AMD

Carl D. Regillo, MD, FACS, reviews long-term efficacy and safety findings from the Port Delivery System clinical trial program.

The FDA's OND found substantial evidence of effectiveness for bevacizumab-vikg in nAMD, clearing the way for a BLA resubmission in June 2026 and a decision expected within 60 days.

The FDA's OND found substantial evidence of effectiveness for bevacizumab-vikg in nAMD, clearing the way for a BLA resubmission in June 2026 and a decision expected within 60 days.

Oral QA102 shows imaging signals slowing drusen and GA progression in intermediate dry AMD at ARVO 2026, despite missing its primary end point.

Bausch + Lomb's PreserVision AREDS3 combines the established AREDS2 micronutrient formula with a B-vitamin complex.

Sunil S. Patel, MD, PhD, of the University of Texas Southwestern Medical Center, breaks down QA102's first-in-class mechanism targeting harmful gut bacteria and retinal inflammation, what the phase 2 drusen volume and GA growth rate data reveal about the therapy's potential, and what a phase 3 program must address to bring an oral AMD treatment to patients without options.

Victor M. Villegas, MD, discusses supraorbital vibration as an adjunct to topical anesthesia in a high-volume retina practice.

Avacincaptad pegol may help preserve driving-related vision in geographic atrophy, but post hoc data did not reach statistical significance.

Oral QA102 shows imaging signals slowing drusen and GA progression in intermediate dry AMD at ARVO 2026, despite missing its primary end point.

New pathways are reshaping the management of retinal disease.

Researchers noted growing evidence supporting an additional role for B vitamins.

New SOL-X extension follows AXPAXLI implant in wet AMD for 3 years, probing 24-week dosing durability, safety and vision protection.

From role models to open doors, Christina Y. Weng, MD, MBA, FASRS, shares insights on career development, women in ophthalmology, evolving training models, and her work as protocol chair for the DRCR Retina Network’s Protocol AO study.

SOL-1 data show AXPAXLI extends wet AMD control, delaying fluid rebound and reducing rescue injections while sustaining vision through 52 weeks.

MALBEC (NCT07440225) is a randomized, double-masked trial evaluating the safety and efficacy of MK-8748 at 2 dose levels versus control (aflibercept 2mg).

Regeneron announced that the FDA has amended the EYLEA HD label after the approval, adding 96-week results from the PULSAR wAMD trial and the PHOTON DME trial.

In the JADE trial, OLN324 demonstrated numerically greater visual acuity gains and evidence of sustained retinal drying with fewer retreatments during a treatment-free follow-up period, compared with faricimab.

Q1 2026 eye-care roundup: first dual-agent presbyopia drop, new EDOF IOL, wet AMD phase 3 win, and gene-therapy advances.

The trial, sponsored by ONL Therapeutics, aims to enroll approximately 324 patients across sites in Europe, the United States, and Canada.

The phase 2a study looks at retinal vascular diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

The trials are evaluating DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).

Study finds low-vision rehab boosts daily function and quality of life, but exposes gaps in long-term data and diverse research.

Real-world nAMD/DME care highlights durable anti-VEGF options and emerging TKIs and gene therapy to cut injection burden, improve vision, and reduce fluid.

Early clinical experience highlights considerations for patient selection, surgical technique, and long-term monitoring in retinal disease.

The superiority primary endpoint at week 36 was met with high statistical significance, and AXPAXLI showed either statistical significance or numerical superiority to aflibercept (2 mg) in key secondary and prespecified exploratory endpoints.